Information Provided By:
Fly News Breaks for May 17, 2018
JNJ
May 17, 2018 | 07:43 EDT
Leerink analyst Danielle Antalffy said she came away from Johnson & Johnson's Medical Devices & Consumer analyst day "increasingly confident" that these segments will be able to return to and outpace overall market growth over 2017-22. The analyst, who still sees J&J ultimately returning to and sustaining a "solid mid-single-digit" revenue growth trajectory with upside potential, reiterates her Outperform rating and $160 price target on Johnson & Johnson shares.
News For JNJ From the Last 2 Days
JNJ
JNJ
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.